Literature DB >> 17888740

Auxotrophic complementation as a selectable marker for stable expression of foreign antigens in Mycobacterium bovis BCG.

Sibele Borsuk1, Tom A Mendum, Michel Quevedo Fagundes, Marcelo Michelon, Cristina Wetzel Cunha, Johnjoe McFadden, Odir Antônio Dellagostin.   

Abstract

Mycobacterium bovis BCG has the potential to be an effective live vector for multivalent vaccines. However, most mycobacterial cloning vectors rely on antibiotic resistance genes as selectable markers, which would be undesirable in any practical vaccine. Here we report the use of auxotrophic complementation as a selectable marker that would be suitable for use in a recombinant vaccine. A BCG auxotrophic for the amino acid leucine was constructed by knocking out the leuD gene by unmarked homologous recombination. Expression of leuD on a plasmid not only allowed complementation, but also acted as a selectable marker. Removal of the kanamycin resistance gene, which remained necessary for plasmid manipulations in Escherichia coli, was accomplished by two different methods: restriction enzyme digestion followed by re-ligation before BCG transformation, or by Cre-loxP in vitro recombination mediated by the bacteriophage P1 Cre Recombinase. Stability of the plasmid was evaluated during in vitro and in vivo growth of the recombinant BCG in comparison to selection by antibiotic resistance. The new system was highly stable even during in vivo growth, as the selective pressure is maintained, whereas the conventional vector was unstable in the absence of selective pressure. This new system will now allow the construction of potential recombinante vaccine strains using stable multicopy plasmid vectors without the inclusion of antibiotic resistance markers.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17888740     DOI: 10.1016/j.tube.2007.07.006

Source DB:  PubMed          Journal:  Tuberculosis (Edinb)        ISSN: 1472-9792            Impact factor:   3.131


  16 in total

Review 1.  Recombinant Mycobacterium bovis BCG as an HIV vaccine vector.

Authors:  Rosamund Chapman; Gerald Chege; Enid Shephard; Helen Stutz; Anna-Lise Williamson
Journal:  Curr HIV Res       Date:  2010-06       Impact factor: 1.581

2.  Stable Expression of Lentiviral Antigens by Quality-Controlled Recombinant Mycobacterium bovis BCG Vectors.

Authors:  Bryan E Hart; Rose Asrican; So-Yon Lim; Jaimie D Sixsmith; Regy Lukose; Sommer J R Souther; Swati D G Rayasam; Joseph W Saelens; Ching-Ju Chen; Sarah A Seay; Linda Berney-Meyer; Leslie Magtanong; Kim Vermeul; Priyadharshini Pajanirassa; Amanda E Jimenez; Tony W Ng; David M Tobin; Steven A Porcelli; Michelle H Larsen; Joern E Schmitz; Barton F Haynes; William R Jacobs; Sunhee Lee; Richard Frothingham
Journal:  Clin Vaccine Immunol       Date:  2015-04-29

3.  Novel antibiotic-free plasmid selection system based on complementation of host auxotrophy in the NAD de novo synthesis pathway.

Authors:  Wei-Ren Dong; Li-Xin Xiang; Jian-Zhong Shao
Journal:  Appl Environ Microbiol       Date:  2010-01-29       Impact factor: 4.792

Review 4.  Auxotrophic Mycobacterium bovis BCG: Updates and Perspectives.

Authors:  Odir Antônio Dellagostin; Sibele Borsuk; Thaís Larré Oliveira; Fabiana Kömmling Seixas
Journal:  Vaccines (Basel)       Date:  2022-05-19

5.  Development of a new generation of vectors for gene expression, gene replacement, and protein-protein interaction studies in mycobacteria.

Authors:  Amit Parikh; Devanand Kumar; Yogesh Chawla; Krishna Kurthkoti; Shazia Khan; Umesh Varshney; Vinay K Nandicoori
Journal:  Appl Environ Microbiol       Date:  2013-01-11       Impact factor: 4.792

6.  Phenotypic and transcriptomic response of auxotrophic Mycobacterium avium subsp. paratuberculosis leuD mutant under environmental stress.

Authors:  Jenn-Wei Chen; Joy Scaria; Yung-Fu Chang
Journal:  PLoS One       Date:  2012-06-04       Impact factor: 3.240

7.  CRISPR/Cas9 Approach to Generate an Auxotrophic BCG Strain for Unmarked Expression of LTAK63 Adjuvant: A Tuberculosis Vaccine Candidate.

Authors:  Luana Moraes; Monalisa Martins Trentini; Dimitrios Fousteris; Silas Fernandes Eto; Ana Marisa Chudzinski-Tavassi; Luciana Cezar de Cerqueira Leite; Alex Issamu Kanno
Journal:  Front Immunol       Date:  2022-03-30       Impact factor: 7.561

8.  Engineering new mycobacterial vaccine design for HIV-TB pediatric vaccine vectored by lysine auxotroph of BCG.

Authors:  Narcís Saubi; Ester Gea-Mallorquí; Pau Ferrer; Carmen Hurtado; Sara Sánchez-Úbeda; Yoshiki Eto; Josep M Gatell; Tomáš Hanke; Joan Joseph
Journal:  Mol Ther Methods Clin Dev       Date:  2014-05-21       Impact factor: 6.698

9.  Stable expression of Mycobacterium bovis antigen 85B in auxotrophic M. bovis bacillus Calmette-Guérin.

Authors:  Caroline Rizzi; Ana Carolina Peiter; Thaís Larré Oliveira; Amilton Clair Pinto Seixas; Karen Silva Leal; Daiane Drawanz Hartwig; Fabiana Kommling Seixas; Sibele Borsuk; Odir Antônio Dellagostin
Journal:  Mem Inst Oswaldo Cruz       Date:  2017-02       Impact factor: 2.743

10.  Vaccination with a BCG strain overexpressing Ag85B protects cattle against Mycobacterium bovis challenge.

Authors:  Caroline Rizzi; María Verónica Bianco; Federico Carlos Blanco; Marcelo Soria; María José Gravisaco; Valeria Montenegro; Lucas Vagnoni; Bryce Buddle; Sergio Garbaccio; Fernando Delgado; Karen Silva Leal; Angel Adrián Cataldi; Odir Antônio Dellagostin; Fabiana Bigi
Journal:  PLoS One       Date:  2012-12-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.